Timing of surgery following neoadjuvant chemoradiotherapy in locally advanced rectal cancer - A comparison of magnetic resonance imaging at two time points and histopathological responses by West, MA et al.
Table 1: Baseline patient characteristics  
 
 
 
Characteristics Values* 
  
 Age (years)  66.2 (10.1) 
Sex [male] 26 (74%) 
  Height of primary tumour (from anal verge) 
Low (0-5cm) 18 (51%) 
Medium/high (>5cm) 17 (49%) 
  
Operation type  
TME 23 (66%) 
APR 10 (29%) 
Palliative 2 (6%) 
 
Tumour stage at baseline on MR  
 T2 8 (23%) 
T3a 6 (17%) 
T3b 4 (11%) 
T3c 4 (11%) 
T3d 2 (6%) 
T4a 5 (14%) 
T4b 1 (3%) 
Poor quality image 5 (14%) 
 
*N=35 patients; values are mean (SD) or n(%). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2 Patient characteristics with full MR imaging and 
histopathology 
 
 
 
Characteristics   Values* 
   
  
MRI tumour T-stage post NACRT (ymrT) 
 Week 9  
 T0 4 (11%) 
T1 1 (3%) 
T2 10 (29%) 
T3a 2 (6%) 
T3b 4 (11%) 
T3c 3 (9%) 
T3d 1 (3%) 
T4a 5 (14%) 
Poor quality image 5 (14%) 
 
Week 14  
 T0 7 (20%) 
T1 5 (14%) 
T2 4 (11%) 
T3a 5 (14%) 
T3b 4 (11%) 
T3c 1 (3%) 
T3d 1 (3%) 
T4a 3 (9%) 
Poor quality image 5 (14.%) 
 
MRI Tumour regression grading (ymrTRG) 
 Week 9  
 1 3 (9%) 
2 10 (29%) 
3 7 (20%) 
4 9 (26%) 
5 1 (3%) 
Poor quality image 5 (14%) 
 
Week 14  
 1 10 (29%) 
2 8 (23%) 
3 5 (14%) 
4 4 (11%) 
5 3 (9%) 
Poor quality image 5 (14%) 
 
 
 
Volume change 
Week 9  
 <80% 20 (57%) 
≥80% 10 (29%) 
Poor quality image 5 (14%) 
 
Week 14  
 <80% 10 (29%) 
≥80% 20 (57%) 
Poor quality image 5 (14%) 
 
Postoperative pathological T-stage(ypT) 
 T0 8 (23%) 
T1 2 (6%) 
T2 7 (20%) 
T3 3 (9%) 
T3a 6 (17%) 
T3b 2 (6%) 
T4a 1 (3%) 
T4b 4 (11%) 
Missing 2 (6%) 
 
Postoperative pathological tumour regression grading 
(ypTRG) 
 0 3 (9%) 
1 8 (23%) 
2 6 (17%) 
3 8 (23%) 
4 8 (23%) 
Missing 2 (6%) 
 
*N=35 patients; values n(%). 
NACRT – neoadjuvant chemoradiotherapy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 3 – Results from logistic regression analysis with pathological T-stage (ypT) as an 
outcome variable 
 
Variable Pathology Outcome OR# 95% CI p-value 
Favourable Unfavourable 
Age (years) mean (SD) 65.5 (10.8) 68 (8.8) 1.0 0.9, 1.1 0.56 
 
Sex 
     
Male 20 6 1.8 0.2, 18.0 0.62  
Female 6 1    
 
Week 9 ymrT-stage 
     
Favourable 16 6 17.8 1.7, 165.0 0.005 
Unfavourable 0 6    
 
Week 14 ymrT-stage 
     
Favourable 19 1 31.7 2.7, 373.7 0.006 
Unfavourable 3 5    
 
Week 9 ymrTRG 
  
   Favourable 17 2 6.8^ 0.9, 48.7 0.056 
Unfavourable 5 4    
 
Week 14 ymrTRG 
     
Favourable 20 2 20.0 2.1, 186.9 0.009 
Unfavourable 2 4    
      
Week 9 volume change      
Favourable 10 0 N/A N/A N/A 
Unfavourable 12 6    
      
Week 14 volume change      
Favourable 
Unfavourable 
18 
1 
4 
5 
22.5 2.0, 249.2 0.011 
Adjusted for baseline   16.7 1.4, 197.1 0.025 
 
# All OR, 95%CI and p-values are unadjusted unless specified otherwise. 
^ Unable to adjust as this is the baseline value  
ymrT - MRI defined tumour T-stage post neoadjuvant chemoradiotherapy;  ymrTRG - MRI 
defined tumour regression grading post neoadjuvant chemoradiotherapy 
 
 
 
 
 
 
 
Table 4 - Logistic regression with pathological tumour regression grading (ypTRG) as 
the outcome variable 
Variable Pathology Outcome OR# 95% CI  p-value 
Favourable Unfavourable 
Age years) mean (SD) 63.9 (45, 88) 68.1 (56, 83) 1.0 0.9, 1.0 0.244 
 
Sex  
     
Male 10 16 9.6 1.0, 92.0 0.052 
Female 6 1    
 
Week 9 ymrT-stage 
     
Favourable  12 4 9.0 1.6, 50.7 0.013 
Unfavourable 3 9    
Adjusted for baseline   3.4 0.7, 16.2 0.128 
 
Week 14 ymrT-stage 
     
Favourable  14 6 16.3 1.6, 163.4 0.017 
Unfavourable 1 7    
Adjusted for baseline   17.5 1.2, 250.4 0.035 
Week 9 ymrTRG      
Favourable  13 6 7.6^ 1.2, 48.0 0.031 
Unfavourable 2 7    
 
Week 14 ymrTRG 
     
Favourable  15 7 14.0* 1.5, 134.2 0.022 
Unfavourable 0 6    
      
Week 9 volume change      
Favourable 8 2 6.3 1.0, 38.7 0.047 
Unfavourable 7 11    
Adjusted for baseline   5.1 0.8, 32.6 0.085 
      
Week 14 volume change      
Favourable 14 1 22.4 2.2, 227 0.009 
Unfavourable 5 8    
Adjusted for baseline   18.7 1.8, 198.9 0.015 
       
^ Unable to adjust as this is the baseline value 
# All OR, 95%CI and p-values are unadjusted unless specified otherwise. 
ymrT - MRI defined tumour T-stage post neoadjuvant chemoradiotherapy;  ymrTRG - MRI 
defined tumour regression grading post neoadjuvant chemoradiotherapy 
 
